Beverly Johnson
Rheumatology · Bronx, NYNPI 1336306992
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $43,647 of the $62,557 with a category attached, or 69.8%. 15 manufacturers reported payments, led by UCB, Inc. at 26.3% of the total. Among rheumatology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $306.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$16K
- E.r. Squibb & Sons, L.L.C.$15K
- Genentech USA, Inc.$7K
- Novartis$6K
- Pfizer$6K
- AbbVie$6K
- plus $7K from 9 others
Across 17 payments — averaging $3796.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$20K
- E.r. Squibb & Sons, L.L.C.$17K
- Genentech, Inc.$15K
- AbbVie$12K
What the payments were for
- Consulting fees$43,64770%
- Speaking & faculty fees$6,86811%
- Travel & lodging$7,18211%
- Food & beverage$4,7818%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 38 | $16,453 |
| E.r. Squibb & Sons, L.L.C. | 13 | $14,660 |
| Genentech USA, Inc. | 14 | $6,605 |
| Novartis | 12 | $6,093 |
| Pfizer | 20 | $5,901 |
| AbbVie | 44 | $5,698 |
| Johnson & Johnson | 5 | $2,314 |
| Lilly USA, LLC | 11 | $1,756 |
| Sanofi | 14 | $1,683 |
| AstraZeneca | 8 | $449 |
| Amgen(2 entities) | 9 | $428 |
| GSK | 7 | $254 |
| Aurinia Pharma U.S., Inc. | 2 | $109 |
| Janssen Scientific Affairs, LLC | 3 | $87 |
| Regeneron Healthcare Solutions, Inc. | 4 | $68 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,557 in reported general payments places this provider in the 90th percentile of 541 rheumatology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 22 | $157,794 |
| BenlystaBelimumab | 22 | $101,975 |
| Humira(Cf) PenAdalimumab | 11 | $73,188 |
| Actemra ActpenTocilizumab | 13 | $30,678 |
| Lidocaine | 14 | $2,097 |
| Leflunomide | 16 | $1,863 |
| Hydroxychloroquine Sulfate | 58 | $1,851 |
| MethotrexateMethotrexate Sodium | 36 | $1,365 |
| Gabapentin | 96 | $981 |
| Diclofenac Sodium | 54 | $707 |
| Alendronate Sodium | 46 | $316 |
| Prednisone | 70 | $244 |
| Pilocarpine Hcl | 13 | $200 |
| Omeprazole | 11 | $112 |
| Meloxicam | 18 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $254 | $101,97522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 541 rheumatology providers in New York.
Other rheumatology in Bronx
- Vinita PatelBronx$73K
- Arlene TiengBronx$51K
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Richard FurieNew Hyde Park$746K
- Barry GruberBabylon$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.